Meeting
2016 Gastrointestinal Cancers Symposium
Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
Authors
Erkut Hasan Borazanci
Virginia G. Piper Cancer Center, TGen, Scottsdale, AZ
Erkut Hasan Borazanci , David S. Hong , Martin Gutierrez , Drew W. Rasco , Tony R. Reid , Michael H. Veeder , Ahmed Tawashi , Jennifer Lin , Isaiah W. Dimery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02403271
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS484)
DOI
10.1200/jco.2016.34.4_suppl.tps484
Abstract #
TPS484
Poster Bd #
O12
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2020 Gastrointestinal Cancers Symposium
Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.
First Author: Thierry Andre
Poster
2019 ASCO Annual Meeting
Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
First Author: Jermaine Coward